Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
HRA Pharma
Age
Any age
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Having received ellaOne® as emergency contraception at the clinical site
Postmenarcheal adolescents or adult women
Willing to provide information on bleeding, sexual intercourses, method of contraception, concomitant medications and adverse events for the next two menstrual periods and to complete the diary accordingly
Willing to provide information on pregnancy outcome / delivery and newborn's health at delivery
Able to provide written informed consent
Willing to not participate in a clinical trial before the end of study participation
You may not be if
Currently participating in any interventional clinical trial (testing an Investigational Medicinal Product)
Clareo Health | Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women
